Q-omics provides the consensus-scored MIR3681HG profile across patient tissues and cancer cell-line models. MIR3681HG expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, MIR3681HG is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MIR3681HG RNA expression shows 9,943 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, KIRC, and TGCT as cancer lineages where MIR3681HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3681HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3681HG survival associations across molecular data types. MIR3681HG RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3681HG RNA expression–survival associations across cancer types. High MIR3681HG expression shows unfavorable associations in LGG, UCS and SARC, but favorable associations in OV, LUSC and DLBC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for MIR3681HG RNA expression.
This table summarizes MIR3681HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3681HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3681HG shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in LIHC, STAD and LUSC. The KIRC box plot shows higher MIR3681HG RNA expression in normal versus tumor tissue (log2 FC = −0.313, t-test p < 0.001).
This table shows molecular features associated with MIR3681HG in patient tissues and cancer cell lines. In patient samples, MIR3681HG shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
